Inventor · disambiguated record
James Garegnani
Also filed as: GAREGNANI JAMES · GAREGNANI JAMES A · GAREGNANI JAMES ALLEN
8 granted patents·32 pending applications·1,457 citations·filing 1989–2024
88Inventor score
Files withLUPIN INC13GAVIS PHARMACEUTICALS10KV PHARM CO6LUPIN ATLANTIS HOLDINGS SA6EVOFEM BIOSCIENCES INC2
Top patents by PatentIndex Score
40 records- 0197US5445829AExtended release pharmaceutical formulationsKV PHARM CO·Filed 1992·Granted Aug 29, 1995·473 cites·68 claims
- 0297US5133974AExtended release pharmaceutical formulationsKV PHARM CO·Filed 1990·Granted Jul 28, 1992·877 cites·29 claims
- 0389US5122384AOral once-per-day organic nitrate formulation which does not induce toleranceKV PHARM CO·Filed 1989·Granted Jun 16, 1992·97 cites·38 claims
- 0478US6793935B2Mineral supplementKV PHARM CO·Filed 2002·Granted Sep 21, 2004·7 cites·26 claims
- 0577US2025333384A1Deuterated secnidazole for use in the treatment of bacterial vaginosis and methods and uses thereofEVOFEM BIOSCIENCES INC·Filed 2024·Application pending·0 cites
- 0673US12172969B2Deuterated secnidazole for use in the treatment of bacterial vaginosis and methods and uses thereofEVOFEM BIOSCIENCES INC·Filed 2022·Granted Dec 24, 2024·0 cites·23 claims
- 0768US2023079420A1Vitamin b12 compound supplementation methods and compositionsLUPIN INC·Filed 2022·Application pending·0 cites
- 0867US2020071279A1Deuterated secnidazole for use in the treatment of bacterial vaginosis and methods and uses thereofLUPIN INC·Filed 2019·Application pending·0 cites
- 0964US11478503B2Vitamin B12 compound supplementation methods and compositionsLUPIN INC·Filed 2020·Granted Oct 25, 2022·0 cites·20 claims
- 1063US2024115490A1Drug delivery system for ultra-low dose estrogen combinations and methods and uses thereofLUPIN INC·Filed 2023·Application pending·0 cites
- 1162US2023404911A1Drug delivery system for ultra-low dose estrogen combinations and methods and uses thereofLUPIN INC·Filed 2023·Application pending·0 cites
- 1259US2023348397A2Deuterated secnidazole for use in the treatment of bacterial vaginosis and methods and uses thereofLUPIN INC·Filed 2022·Application pending·0 cites
- 1356US2003108605A1Mineral supplementKV PHARM CO·Filed 2002·Application pending·0 cites
- 1453US2016158212A1Extended release aqueous suspension of methylphenidate or salts thereofGAVIS PHARMACEUTICALS·Filed 2014·Application pending·0 cites
- 1553US2016166702A1Extended release aqueous suspension of methylphenidate or salts thereofGAVIS PHARMACEUTICALS·Filed 2014·Application pending·0 cites
- 1653US2016175257A1Solid oral dosage form of methylphenidate or salts thereofGAVIS PHARMACEUTICALS·Filed 2014·Application pending·0 cites
- 1752US2020179274A1Drug delivery system for ultra-low dose estrogen combinations and methods and uses thereofLUPIN INC·Filed 2019·Application pending·0 cites
- 1851US2021015755A1Secnidazole soft gelatin capsule and methods and uses thereofLUPIN INC·Filed 2019·Application pending·0 cites
- 1950US11400093B2Deuterated elagolix-like compositions and methodsLUPIN INC·Filed 2020·Granted Aug 2, 2022·0 cites·35 claims
- 2049US2019224177A1Stable liquid compositions of sodium picosulfateLUPIN INC·Filed 2018·Application pending·0 cites
- 2149US2019183817A1Extended release suspensions of mixtures of dextro- and levo-amphetaminesLUPIN INC·Filed 2018·Application pending·0 cites
- 2246US2018318214A1Pharmaceutical compositions of dronabinolLUPIN ATLANTIS HOLDINGS SA·Filed 2018·Application pending·0 cites
- 2345US2018161281A1Extended release pharmaceutical composition of mixed amphetaminesLUPIN ATLANTIS HOLDINGS SA·Filed 2017·Application pending·0 cites
- 2444US2018110737A1Extended-release oral pharmaceutical composition of amphetamineGAVIS PHARMACEUTICALS·Filed 2017·Application pending·0 cites
- 2543US2018098942A1Oral pharmaceutical composition of methylergonovine and methods of use thereofLUPIN ATLANTIS HOLDINGS SA·Filed 2017·Application pending·0 cites
- 2643US2018116952A1Oral pharmaceutical composition of methylergonovine and methods of use thereofLUPIN ATLANTIS HOLDINGS SA·Filed 2017·Application pending·0 cites
- 2743US2018116953A1Oral pharmaceutical composition of methylergonovine and methods of use thereofLUPIN ATLANTIS HOLDINGS SA·Filed 2017·Application pending·0 cites
- 2843US2018098982A1Oral pharmaceutical composition of methylergonovine and methods of use thereofLUPIN ATLANTIS HOLDINGS SA·Filed 2017·Application pending·0 cites
- 2942US2016339015A1Oral pharmaceutical composition of methylergonovineLUPIN INC·Filed 2016·Application pending·0 cites
- 3041US2017348239A1Solid oral pharmaceutical compositionLUPIN INC·Filed 2016·Application pending·0 cites
- 3141US2016271120A1Pharmaceutical composition for cleansing of the gastrointestinal tractOAKDENE HOLDINGS LLC·Filed 2016·Application pending·0 cites
- 3241US2016243144A1Fixed dose combination formulations of rifaximin and lactuloseOAKDENE HOLDINGS LLC·Filed 2016·Application pending·0 cites
- 3340US2016243064A1Novel oral pharmaceutical compositions of treprostinilGAVIS PHARMACEUTICALS·Filed 2016·Application pending·0 cites
- 3440US2016263152A1Bowel cleansing composition with improved tasteGAVIS PHARMACEUTICALS·Filed 2016·Application pending·0 cites
- 3538US2016220562A1Pharmaceutical composition of bupropion and naltrexoneGravis Pharmaceuticals·Filed 2015·Application pending·0 cites
- 3638US2016220492A1Pharmaceutical composition of sodium picosulfateGAVIS PHARMACEUTICALS·Filed 2015·Application pending·0 cites
- 3738US2016263102A1Pharmaceutical composition of bupropion and naltrexoneGAVIS PHARMACEUTICALS·Filed 2015·Application pending·0 cites
- 3838US2016220544A1Pharmaceutical composition of sodium picosulfateGAVIS PHARMACEUTICALS·Filed 2015·Application pending·0 cites
- 3938US2016220561A1Pharmaceutical composition of bupropion and naltrexoneGAVIS PHARMACEUTICALS·Filed 2015·Application pending·0 cites
- 4034US5296232APharmaceutical formulation which does not induce toleranceKV PHARM CO·Filed 1992·Granted Mar 22, 1994·3 cites·16 claims
Join the waitlist — get patent alerts
Get an alert when James Garegnani files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →